```
=> d his

     (FILE 'HOME' ENTERED AT 15:33:14 ON 19 MAR 2003)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
     BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
     CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
     DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 15:33:58 ON
     19 MAR 2003
               SEA CD20(10W)B CELL
               ---------
              47   FILE ADISCTI
               4   FILE ADISINSIGHT
               8   FILE ADISNEWS
               2   FILE BIOBUSINESS
               7   FILE BIOCOMMERCE
             324   FILE BIOSIS
               6   FILE BIOTECHABS
               6   FILE BIOTECHDS
             105   FILE BIOTECHNO
               4   FILE CABA
             215   FILE CANCERLIT
             229   FILE CAPLUS
               5   FILE CEABA-VTB
              26   FILE CIN
              13   FILE CONFSCI
              68   FILE DDFU
            9287   FILE DGENE
              11   FILE DRUGNL
              89   FILE DRUGU
               3   FILE DRUGUPDATES
               7   FILE EMBAL
             238   FILE EMBASE
             126   FILE ESBIOBASE
              12   FILE FEDRIP
              23   FILE GENBANK
              16   FILE IFIPAT
              34   FILE JICST-EPLUS
              52   FILE LIFESCI
             262   FILE MEDLINE
               1   FILE NIOSHTIC
              16   FILE PASCAL
               4   FILE PHAR
              16   FILE PHARMAML
              15   FILE PHIN
              98   FILE PROMT
             250   FILE SCISEARCH
             164   FILE TOXCENTER
             162   FILE USPATFULL
              16   FILE WPIDS
              16   FILE WPINDEX
L1              QUE CD20(10W) B CELL
                ---------

     FILE 'DGENE, BIOSIS, MEDLINE, SCISEARCH, EMBASE, CAPLUS, CANCERLIT,
     TOXCENTER, USPATFULL, ESBIOBASE, BIOTECHNO, PROMT, DRUGU, LIFESCI,
     ADISCTI, JICST-EPLUS, CIN, GENBANK, IFIPAT, PASCAL, PHARMAML, WPIDS,
     PHIN, CONFSCI, FEDRIP, DRUGNL, ADISNEWS, BIOCOMMERCE, ...' ENTERED AT
     15:35:41 ON 19 MAR 2003
L2         11897 S CD20(10W)B CELL
L3            39 S VACCIN?(10W)CD20
```

```
L4          18 DUP REM L3 (21 DUPLICATES REMOVED)
L5          42 S CD20(25W)(EXTRACELL?) AND DOMAIN
L6          30 DUP REM L5 (12 DUPLICATES REMOVED)
L7        5691 S CD20(10W)ANTIBOD?
L8          17 S L7 AND CD10(10W)(ANTIGEN OR IMMUNOGEN?)
L9          16 DUP REM L8 (1 DUPLICATE REMOVED)
L10        372 S B1(20W)CD20 AND (B CELL)
L11        148 DUP REM L10 (224 DUPLICATES REMOVED)
L12        166 S L10 AND B1(25W)ANTIBOD?
L13         75 DUP REM L12 (91 DUPLICATES REMOVED)
L14        425 S B1(25W)VACCINE
L15        250 DUP REM L14 (175 DUPLICATES REMOVED)
L16         19 S L14 AND (CANCER OR TUMOR OR TUMOUR)
L17         15 DUP REM L16 (4 DUPLICATES REMOVED)

=>
```

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1997:8270 CAPLUS
DN 126:103042
TI Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide
AU Hooijberg, Erik; Visseren, Marjan J. W.; Van Den Berk, Paul C. M.; Jellema, Anke P.; Romeijn, Petra; Sein, Johan J.; Van Der Voort, Ellen I. H.; Hekman, Annemarie; Ossendorp, Ferry; Melief, Cornelis J. M.
CS Department of Immunology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam, Neth.
SO Journal of Immunotherapy with Emphasis on Tumor Immunology (1996), 19(5), 346-356
CODEN: JIEIEZ; ISSN: 1067-5582
PB Lippincott-Raven
DT Journal
LA English
AB Cytotoxic T lymphocytes (CTL) play an important role in the destruction of immunogenic tumors. A novel category of target antigens for CTL concerns normal differentiation antigens as most clearly demonstrated in human melanoma. In the case of B-cell cancers, differentiation antigens normally expressed on B cells may be useful targets. In this report, we have focused on the murine B-cell differentiation antigens CD19 and CD20. We have identified 18 peptide sequences on the basis of major histocompatibility complex (MHC) class-I binding-motifs as candidates for the induction of autoreactive CTL. Six of the peptides were capable of binding efficiently to either Kb or Db and were subsequently used for in vivo induction of CTL. Vaccination with each of three peptides led to peptide-specific CTL. Two peptides were derived from the mCD20 antigen and one from the mCD19 antigen. CTL specific for the mCD19-derived peptide were also capable of killing a syngeneic B-cell tumor line. Recognition of the peptide as well as the tumor cells was shown to be Kb restricted. This is the first report to show that autoreactive CTL recognizing peptides derived from B-cell-specific differentiation antigens can be generated by vaccination with a synthetic peptide.
IT Lymphoma
(B-cell; **vaccination** with CD19 or **CD20** peptides induces cytotoxic T-lymphocytes that lyse syngeneic B-cell tumors in mice)
IT 185856-50-2 185856-51-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**vaccination** with CD19 or **CD20** peptides induces cytotoxic T-lymphocytes that lyse syngeneic B-cell tumors in mice)

Also work on the peptide